Madrigal pharmaceuticals announces $300+ million in financing events to advance resmetirom program

Conshohocken, pa., dec. 21, 2022 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its hercules credit facility.
MDGL Ratings Summary
MDGL Quant Ranking